Tempus AI acquires Paige in an $81.25 million deal, adding FDA-cleared cancer detection tools and a dataset of 7 million ...

Tempus AI shares were higher after the company said it agreed to buy Paige, an AI company focused on digital pathology, for $81.3 million. The stock was up 8.4% at $83.17 and has more than doubled so ...

Tempus AI shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 88.

Tempus AI has acquired the digital pathology developer Paige, including its FDA-cleared, artificial intelligence-powered ...

In buying Paige, Tempus grows its dataset, expands its tech team and gains a foothold in digital pathology, the company said.

Tempus AI (NASDAQ:TEM) announced on Friday an acquisition of the AI company specializing in digital pathology, Paige, for $81 ...

Tempus AI achieves strong revenue growth and beats expectations, but ongoing losses and execution risks temper enthusiasm.

Tempus AI was targeted by a short seller last week. Since then, the company has made several announcements that have helped quell doubts introduced by the short report. The company's stock jumped ...

Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting ...

Completing its initial public offering on June 14, Tempus AI stock closed at $40.25, and while it rose above this mark from time to time in the second half of 2024, the stock ended the year on a ...

Tempus AI, Inc. (NASDAQ:TEM – Get Free Report) shares dropped 3.1% during trading on Wednesday after Piper Sandler lowered their price target on the stock from $70.00 to $55.00. Piper Sandler ...